Hana Plonkova

Ostrava, MO, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma.

Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma.

Journal: HemaSphere
Published: May 20, 2026

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma.

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma.

Journal: HemaSphere
Published: June 21, 2025

Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.

Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.

Journal: Blood cancer discovery
Published: May 15, 2025

Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre-Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients.

Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre-Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients.

Journal: American journal of hematology
Published: November 04, 2024

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic.

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic.

Journal: Cancer medicine
Published: October 07, 2024

Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.

Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.

Journal: European journal of haematology
Published: August 08, 2024

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.

Journal: Leukemia
Published: December 12, 2023

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.

Journal: Cancers
Published: September 07, 2022

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.

Journal: Leukemia
Published: April 24, 2021

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.

Journal: BMC cancer
Published: July 20, 2020

Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.

Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.

Journal: Hematological oncology
Published: March 02, 2020

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.

Journal: Annals of hematology
Published: December 08, 2019
Showing 1-12 of 17

Last Updated: 09/26/2026